Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 17/20 | 0.55 |
| ▸ | DRD2 | P14416 | 5/20 | 0.55 |
| ▸ | DRD3 | P35462 | 5/20 | 0.55 |
| ▸ | CDK4 | P11802 | 1/20 | 0.48 |
| ▸ | CCND1 | P24385 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4573122 | 0.95 | HTR1A (0.54) | HTR1ADRD2DRD3CDK4CCND1 | |
| SCHEMBL7005388 | 0.82 | HPGD (0.55) | CDK4CCND1USP2ALDH1A1HPGD | |
| SCHEMBL10637456 | 0.81 | HTR1A (0.45) | HTR1ADRD2DRD3CDK4CCND1 | |
| SCHEMBL97632 | 0.80 | HTR3A (0.48) | HTR1ADRD2DRD3 | |
| SCHEMBL9309089 | 0.80 | USP2 (0.43) | HTR1ADRD2DRD3CDK4CCND1 | |
| SCHEMBL377396 | 0.79 | HTR1A (0.51) | HTR1ADRD2DRD3CDK4CCND1 | |
| SCHEMBL12628017 | 0.78 | MAPT (0.42) | HTR1ADRD2DRD3CDK4CCND1 | |
| SCHEMBL7004582 | 0.78 | HPGD (0.50) | CDK4CCND1USP2ALDH1A1HPGD | |
| SCHEMBL12628018 | 0.76 | ADRB2 (0.43) | HTR1ADRD2DRD3 | |
| SCHEMBL8616515 | 0.76 | HTR1A (0.42) | HTR1ADRD2DRD3CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606533-B2 | 3-phenylpropylamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-04-21 | — | — | US | disclosed |
| US-20250353824-A1 | 3-PHENYLPROPYLAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-11-20 | — | — | US | disclosed |
| WO-2024259303-A1 | COMPOUNDS AND COMPOSITIONS AS CEREBLON LIGANDS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2024-12-19 | — | — | WO | disclosed |
| EP-3998268-B1 | COMPOUND FOR INHIBITING EGFR KINASE AND PREPARATION METHOD AND USE THEREOF | WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) | 2024-12-18 | — | — | EP | disclosed |
| US-11993598-B2 | Compounds for inhibiting EGFR kinase, preparation methods and uses thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2024-05-28 | — | — | US | disclosed |
| WO-2023287130-A1 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | 한국화학연구원 | 2023-01-19 | — | — | WO | disclosed |
| CN-114026090-B | Compound for inhibiting EGFR kinase and preparation method and application thereof | 微境生物医药科技(上海)有限公司 | 2023-01-06 | — | — | CN | disclosed |
| EP-3998268-A1 | COMPOUND FOR INHIBITING EGFR KINASE AND PREPARATION METHOD AND USE THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2022-05-18 | — | — | EP | disclosed |
| EP-3998268-A1 | COMPOUND FOR INHIBITING EGFR KINASE AND PREPARATION METHOD AND USE THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2022-05-18 | — | — | EP | disclosed |
| CN-114026090-A | Compound for inhibiting EGFR kinase and preparation method and application thereof | 微境生物医药科技(上海)有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-5589476-A | TREATMENT OF NAUSEA, VOMITING AND GASTROINTESTINAL DISORDERS | SYNTHELABO (FR) | 1996-12-31 | — | — | US | disclosed |
| US-5563272-A | ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1996-10-08 | — | — | US | disclosed |
| US-5500423-A | ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1996-03-19 | — | — | US | disclosed |
| EP-0700913-A1 | 5,6-dihydro-4H-imidazo(4,5,1-ij)quinolines, processes for their preparation, their use as medicaments, and intermediate compounds | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1996-03-13 | — | — | EP | disclosed |
| EP-0646583-A1 | Derivatives of Imidezol-4-yl piperidine, their preparation and use in therapy | SYNTHELABO (FR) | 1995-04-05 | — | — | EP | disclosed |
| US-5326768-A | 5-hydroxytryptamine antagonists | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1994-07-05 | — | — | US | disclosed |
| US-5183822-A | 5-hydroxytryptamine receptor antagonistsw | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1993-02-02 | — | — | US | disclosed |
| US-5114949-A | Treating disorders associated with 5HT uptake | RHONE-POULENC SANTE (FR) | 1992-05-19 | — | — | US | disclosed |
| EP-0436245-A1 | Substituted 3,4-annelated benzimidazol-2(1H)-ones | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1991-07-10 | — | — | EP | disclosed |
| WO-1990015058-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | THE UPJOHN COMPANY (US) | 1990-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353824-A1 | 3-PHENYLPROPYLAMINE DERIVATIVE | SF1, SF3A1, SFXN1 | HTR1A 23/4885DRD2 1627/4885DRD3 1738/4885 |
| US-12606533-B2 | 3-phenylpropylamine derivative | SF3A1, SF1, HTR1D | HTR1A 5/4885DRD2 1030/4885DRD3 1105/4885 |
| US-11993598-B2 | Compounds for inhibiting EGFR kinase, preparation methods and uses thereof | EGFR, ERBB2, ERBB4 | HTR1A 4820/4885DRD2 4745/4885DRD3 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.